QRS interval widening appears to be highly specific for the diagnosis of hyperkalemia in patients with end-stage kidney disease. ECG changes, in general, have poor sensitivities for hyperkalemia in ...
AliveCor has received approval from the Food and Drug Administration (FDA) to develop a non-invasive method of detecting high blood potassium levels. The startup, which chiefly focuses on monitoring ...
In patients with severe hyperkalemia, the Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality. Among patients with severe hyperkalemia ...
Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...
NEW YORK--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ Guard TM, an FDA Breakthrough Device ...
AliveCor already offers the first FDA-approved EKG reader for Apple Watch with its Kardiaband system, and a new study shows how that hardware may be capable of even more medical achievements. A new ...
The AliveCor KardiaBand, a sensor compatible with the Apple Watch, can detect dangerous levels of potassium in blood with 94 percent accuracy. Though the US Food and Drug Administration has not yet ...
An AliveCor algorithm has identified people with high potassium levels from electrocardiogram (ECG) data. Limited prospective clinical testing suggests pairing the algorithm with AliveCor’s smartphone ...
The treatment of hyperkalemia can require urgent measures. Fortunately, it can usually be preemptively managed before serum K+ values become dangerously high. The urgency with which therapy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results